The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
Adult
Aged
Allografts
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Combined Modality Therapy
Female
Humans
Kaplan-Meier Estimate
Lymphoma, B-Cell
/ drug therapy
Male
Middle Aged
Peripheral Blood Stem Cell Transplantation
Prognosis
Progression-Free Survival
Proportional Hazards Models
Retrospective Studies
Salvage Therapy
Transplantation, Autologous
Treatment Outcome
Whole-Body Irradiation
Young Adult
Aggressive B-cell lymphoma
Autologous stem cell transplantation
DLBCL
HL
MCL
PCNSL
Prognostic factors
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
12
04
2021
accepted:
19
08
2021
pubmed:
4
9
2021
medline:
26
10
2021
entrez:
3
9
2021
Statut:
ppublish
Résumé
Patients with high-risk or relapsed aggressive B-cell lymphomas are characterized by poor prognosis. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) can induce durable remissions in these patients and is potentially curative. Two hundred forty-seven patients with aggressive B-cell lymphomas treated with high-dose chemotherapy and ASCT, either as consolidation after first-line therapy or after salvage therapy for relapsed disease, between 2002 and 2019 at the University Hospital Muenster, were analyzed. The median follow-up of surviving patients was 36 months (range 0-163). Progression-free survival (PFS) and overall survival (OS) after 3 years was 63% and 68%, respectively. After ASCT, 28% of all patients experienced a relapse. The cumulative incidence of non-relapse mortality at day 100 after ASCT was 4%. Multivariate analysis identified remission status at ASCT, age at ASCT, and the numbers of infused CD34
Identifiants
pubmed: 34477953
doi: 10.1007/s00277-021-04650-5
pii: 10.1007/s00277-021-04650-5
pmc: PMC8510902
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2733-2744Informations de copyright
© 2021. The Author(s).
Références
Ann Oncol. 2005 Apr;16(4):625-33
pubmed: 15737986
Ann Oncol. 2012 Oct;23(10):2670-2675
pubmed: 22473593
J Clin Oncol. 2011 Nov 10;29(32):4234-42
pubmed: 21990399
J Clin Oncol. 2002 Jan 15;20(2):467-75
pubmed: 11786576
Blood. 2008 Oct 1;112(7):2687-93
pubmed: 18625886
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2016 Sep 22;128(12):1562-6
pubmed: 27432875
Bone Marrow Transplant. 2016 Jan;51(1):51-7
pubmed: 26367239
J Clin Oncol. 2014 Nov 1;32(31):3490-6
pubmed: 25267740
Haematologica. 2013 May;98(5):765-70
pubmed: 23300179
Cell Transplant. 2020 Jan-Dec;29:963689720975397
pubmed: 33238731
Lancet. 2016 Aug 6;388(10044):565-75
pubmed: 27313086
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
J Clin Oncol. 2005 Jul 20;23(21):4634-42
pubmed: 15837968
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Curr Hematol Malig Rep. 2016 Jun;11(3):196-207
pubmed: 26983957
Lancet Haematol. 2017 Nov;4(11):e510-e523
pubmed: 29054815
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Ann Oncol. 2017 Jun 1;28(6):1352-1358
pubmed: 28327958
Int J Hematol. 2020 Feb;111(2):256-266
pubmed: 31732878
J Clin Oncol. 2019 Apr 1;37(10):823-833
pubmed: 30785830
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Br J Haematol. 2008 Nov;143(3):395-403
pubmed: 18759762
Ann Oncol. 2013 Sep;24(9):2430-4
pubmed: 23712545
J Clin Oncol. 2009 Sep 20;27(27):4548-54
pubmed: 19704068
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):409-415.e1
pubmed: 25816932
Br J Haematol. 2005 Oct;131(2):223-30
pubmed: 16197454
Bone Marrow Transplant. 2016 Oct;51(10):1397-1399
pubmed: 27214072
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Lancet Oncol. 2011 Oct;12(11):1013-22
pubmed: 21940214
Cancer. 2017 Aug 15;123(16):3073-3079
pubmed: 28369839
J Clin Oncol. 2000 Jan;18(2):332-9
pubmed: 10637247
Br J Haematol. 2012 Aug;158(3):355-62
pubmed: 22640180
J Clin Oncol. 2011 Apr 1;29(10):1342-8
pubmed: 21321299
Lancet. 2002 Jun 15;359(9323):2065-71
pubmed: 12086759
Blood. 2005 Jun 1;105(11):4215-22
pubmed: 15701723
Biol Blood Marrow Transplant. 2014 Jul;20(7):937-45
pubmed: 24631736
Blood. 2015 Feb 26;125(9):1403-10
pubmed: 25568347
Lancet Oncol. 2012 Dec;13(12):1250-9
pubmed: 23168367
Lancet Oncol. 2014 Jun;15(7):757-66
pubmed: 24827808
Bone Marrow Transplant. 1997 Sep;20(6):451-8
pubmed: 9313877
Cochrane Database Syst Rev. 2013 Jun 20;(6):CD009411
pubmed: 23784872
Blood. 2019 Oct 3;134(14):1144-1153
pubmed: 31409671
Exp Hematol Oncol. 2019 Mar 18;8:7
pubmed: 30923643